OncoSec Medical, a developer of OMS ElectroOncology therapies for the treatment of solid-tumour cancers, has submitted the device master file for its patented OncoSec Medical System to the US Food and Drug Administration (FDA).

The OncoSec Medical System is comprised of a generator and a handheld applicator, and is deisgned to deliver DNA-based cytokines and chemotherapeutic agents.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Clinical trials have shown the OncoSec Medical System to be both safe and effective at optimising the cellular uptake of these agents, resulting in improved therapeutic benefits for the patient.

The regulatory filing includes technical, manufacturing, clinical and non-clinical information about the OncoSec Medical System, which will facilitate an FDA review of the complete system.

OncoSec plans to initiate three Phase II clinical trials using the system: OMS-I100 for the treatment of melanoma, OMS-I120 for the treatment of Merkel cell carcinoma, and OMS-I130 for the treatment of cutaneous T-cell lymphoma.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact